GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

CID-078   Click here for help

GtoPdb Ligand ID: 14495

Compound class: Peptide
Comment: CID-078 is an orally bioavailable macrocyclic peptide molecule, optimised for clinical application from the experimental macrocycle CIRc-014. Like its parent, CID-078 disrupts the protein-protein interactions between cyclins A and B and their cognate cyclin-dependent kinases (CDKs), as an anti-tumpour mechanism. The peptide binds to the same RxL motif within the conserved hydrophobic patch on the surface of the cyclins as CIRc-014.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CC(C)C[C@H]1C(=O)N(C)[C@H](CC2=C(C=CC(=C2)Cl)C3=CN(C)N=C3)C(=O)N(C)CCCCCCC[C@@H](C(=O)N1)N(C)C(=O)[C@@H](C4CC4)NC(=O)[C@H]5C[C@@H](CN5C(=O)C6(CC(C6)(F)F)C(F)(F)F)F
Isomeric SMILES CC(C)C[C@@H]1NC(=O)[C@H](CCCCCCCN(C)C(=O)[C@@H](CC2=C(C=CC(Cl)=C2)C3=CN(C)N=C3)N(C)C1=O)N(C)C(=O)[C@H](NC(=O)[C@H]4C[C@H](F)CN4C(=O)C5(CC(F)(F)C5)C(F)(F)F)C6CC6
InChI InChI=1S/C47H63ClF6N8O6/c1-27(2)18-34-41(65)61(6)37(20-29-19-31(48)15-16-33(29)30-22-55-59(4)23-30)42(66)58(3)17-11-9-7-8-10-12-35(39(63)56-34)60(5)43(67)38(28-13-14-28)57-40(64)36-21-32(49)24-62(36)44(68)45(47(52,53)54)25-46(50,51)26-45/h15-16,19,22-23,27-28,32,34-38H,7-14,17-18,20-21,24-26H2,1-6H3,(H,56,63)(H,57,64)/t32-,34-,35-,36+,37+,38+/m0/s1
InChI Key LSUMJDILBCWSIG-UQJCHVLTSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
CID-078 was progressed as a clinical candidate for the treatment of advanced solid tumours, with a particular interest in patients whose tumours harbour deleterious genomic variants that cause high E2F transcription factor activity, or retinoblastoma 1 protein loss of function mutations.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06577987 Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies Phase 1 Interventional Circle Pharma